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ABSTRACT 
Objective: There is initial evidence that the use of volatile anesthetics can reduce the postoperative 
release of cardiac troponin I, the need for inotropic support, and the number of patients requiring 
prolonged hospitalization following coronary artery bypass graft (CABG) surgery. Nevertheless, 
small Randomized Controlled Trials have failed to demonstrate a survival advantage. Thus, whether 
volatile anesthetics improve the postoperative outcome of cardiac surgical patients remains 
uncertain. An adequately powered randomized controlled trial appears desirable. 
Design: Single blinded, international, multicenter randomized controlled trial with 1:1 allocation 
ratio. 
Setting: Tertiary and University hospitals. 
Interventions: Patients (n= 10,600) undergoing coronary artery bypass graft will be randomized to 
receive either volatile anesthetic as part of the anesthetic plan, or total intravenous anesthesia. 
Measurements and main results: The primary end point of the study will be one-year mortality 
(any cause). Secondary endpoints will be 30-day mortality; 30-day death or non-fatal myocardial 
infarction (composite endpoint); cardiac mortality at 30 day and at one year; incidence of hospital 
re-admission during the one year follow-up period and duration of intensive care unit, and hospital 
stay. The sample size is based on the hypothesis that volatile anesthetics will reduce 1-year 
unadjusted mortality from 3% to 2%, using a two-sided alpha error of 0.05, and a power of 0.9. 
Conclusions: The trial will determine whether the simple intervention of adding a volatile 
anesthetic, an intervention that can be implemented by all anesthesiologists, can improve one-year 
survival in patients undergoing coronary artery bypass graft surgery. 
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INTRODUCTION 
Coronary artery disease (CAD) remains one of the most common causes of death and significantly 
affects the use of health care resources. In the United States alone, it results in more than 397,000 
Coronary Artery Bypass Grafting (CABG) surgeries per year.1 There is initial evidence that the 
choice of anesthesia can influence survival in the specific setting of CABG. An international 
consensus conference considered volatile anesthetics among the few drugs, techniques or strategies 
that might reduce perioperative mortality in cardiac surgery and should be further studied.2 
All volatile anesthetics have cardiac depressant effects but also a beneficial effect on the myocardial 
oxygen balance during ischemia.3,4 Animal trials have shown that volatile anesthetics can provide 
protection against the ischemia-reperfusion injury that occurs during cardiac surgery via 
preservation of mitochondrial function and improved cell survival.22 Furthermore volatile 
anesthetics reduce the inflammatory response seen in acute lung injury,5,6 and after brain,7 liver8 and 
kidney9 ischemia with associated clinical benefits. The most recent and comprehensive meta-
analysis10 of 68 randomized controlled trials (RCTs) included 7,104 patients and compared volatile 
anesthetics with total intra-venous anesthesia (TIVA). It showed that in cardiac surgery volatile 
anesthetics are associated with reduced overall mortality (OR 0.55, 95% CI 0.35–0.85, p=0.007), 
reduced pulmonary complications (OR 0.71, 95% CI 0.52–0.98, p=0.038) and a reduction in other 
complications (OR 0.74, 95% CI 0.58–0.95, p=0.020). The largest multicenter study published so 
far on this topic by De Hert et al.11 randomized 414 participants undergoing on-pump CABG. In 
this study one-year mortality was a secondary outcome and was different among groups (12.3% in 
the TIVA group, 6.9% in the Desflurane group, and 3.3% in the Sevoflurane group; p=0.034). A 
further recently published RCT suggested a mortality reduction at 1 year in the sevoflurane group 
when compared to the TIVA group12. A previous large observational study13 and a long-term 
follow-up of a RCT14 found that the occurrence of complications in the postoperative period was an 
independent predictors of long-term survival, supporting the notion that perioperative organ 
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protection and reduction in postoperative complications with volatile anesthetics could decrease 
long-term mortality. 
Therefore, we aim to carry out the MYRIAD trial (MortalitY in caRdIAc surgery. A randomizeD 
controlled trial of volatile anesthetics in cardiac surgery) a large multicenter RCT to identify 
whether a clinically important reduction in one-year mortality from 3% to 2% after CABG surgery 
can be achieved by including a volatile anesthetic as part of the overall anesthetic in patients 
receiving TIVA or volatile agents.  
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MATERIALS AND METHODS 
Study design, approval, and registration 
The planned study is a parallel group, randomized controlled, single-blinded multicenter trial with 
1:1 allocation ratio. The study has been approved by the Human Research Ethics Committee of all 
the participating centers and is registered on clinicaltrials.gov as NCT02105610. 
Study aim 
The aim of our study is to test the hypothesis that volatile anesthetics can reduce one-year mortality 
from 3% to 2% in participants undergoing CABG, either with or without cardiopulmonary bypass 
(CPB). 
Participants 
We plan to enroll 10,600 participants with CAD undergoing elective CABG. Participants will be 
>18 years and undergoing scheduled isolated CABG (including multiple coronary artery bypass). 
The exclusion criteria are presented in Table 1. 
Inclusion Criteria Exclusion Criteria 
Age > 18 years Planned: 
- Valve surgery 
- Surgery of the aorta 
Scheduled procedure Unstable/ongoing angina 
Isolated coronary artery bypass graft Acute myocardial infarction (<1 month) 
 Use of: 
- Sulfonylurea 
- Theophylline 
- Allopurinol 
 Previous unusual response to an anesthetic agent 
 Inclusion in other randomized controlled studies in the 
previous 30 days 
 Any general anesthesia performed in the previous 30 days 
 Emergency operation 
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 Kidney or liver transplant in medical history 
 Liver cirrhosis (Child B or C) 
 
Table 1: MYRIAD inclusion and exclusion criteria 
 
Randomization, allocation and concealment 
 
Subjects will be allocated according to a web-based centralized randomization service or by 
opening centrally provided sealed opaque envelopes with the use of a permuted-block design 
stratified according to center. We will use randomization blocks of 20. Patients will be unaware of 
group assignments. Anesthesiologists will provide the trial treatment intervention and, as a 
consequence, will know patients’ group allocation but will not be involved in postoperative 
treatment, data collection, data entry or data analysis. Investigators and clinical personnel caring for 
patients, including intensive care physicians, will be blinded to the study drug for the duration of the 
trial. Data will be collected by trained observers who will not participate in patient care and will be 
blinded to patient allocation. 
 
Interventions 
Participants will be randomized to receive either anesthesia which includes a volatile agent or TIVA 
alone (Fig.1). 
The volatile group will receive desflurane, isoflurane or sevoflurane to provide general anesthesia in 
addition to any intravenous agent (according to local protocols and expertise). The volatile agent 
will be administered for as long as possible (ideally from anesthesia induction to ICU sedation) and 
at the highest concentration permitted by local protocols and patient hemodynamics during at least 
one of the following time periods: anesthesia induction, pre-CPB, during CPB, after CPB in the 
surgical theatre, and in the ICU.  
Within the volatile group the following strategies are strongly suggested but not mandatory: a) at 
least 1 minimal alveolar concentration (MAC) for at least 30 minutes (this is the minimum 
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concentration demonstrated to be cardioprotective in experimental studies); b) discontinuation of 
the volatile agent for at least 15 minutes before CPB (a wash-out period before ischemia seems to 
be a prerequisite for the preconditioning phenomenon); c) wash-in/wash-out periods, defined as: 
volatile administration (at least 0.5 MAC) for at least three periods of 10 minutes, interspersed by 
wash-out periods of 10 minutes or more. 
The aim of these strategies is to enhance the cardio-protective properties of volatile agents23,24 
without significantly modifying the local protocols and without affecting patient safety. 
The TIVA group will receive any intravenous agent and no volatile agent. Agents for TIVA will be 
administered as both target-controlled infusions or manually controlled infusions according to local 
protocols and expertise. 
In case of repeated operation during the first hospitalization the patients will follow the study 
allocated anesthesia. 
This is a pragmatic study. Accordingly, we have chosen not to require or define a strict anesthetic 
protocol. This allows all patients to be treated according to the best available treatment available in 
each center. We consider that this approach adds external validity to future findings. 
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CABG: Coronary artery bypass graft; TIVA: Total intravenous anesthesia. 
Figure 1: MYRIAD Flow chart.  
 
All participants will receive perioperative intensive treatment according to their institutional 
practice, including general anesthesia, pacing, inotropic drugs, mechanical ventilation, 
postoperative sedation/analgesia, diuretics, intravenous fluids, antibiotics and invasive monitoring. 
Such treatment will include but not be limited to, invasive arterial pressure, electrocardiogram, 
central venous pressure, cardiac output, pulse oximetry, temperature, urine output, arterial blood 
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gases and frequent routine laboratory examinations. No additional intervention or laboratory 
examination will be performed on participants outside of institutional practice. 
 
Data will be collected at the end of surgical intervention, at ICU discharge, and at hospital 
discharge. We will record data about dosage, timing and mode of administration of all drugs used 
for the anesthesia. Surgical characteristics including CPB and aortic cross-clamping duration will 
also be collected. With regards to volatile anaesthetic use, we will collect data on what agent was 
administered, what dose, for how long and at what time points (induction, before CPB or the start of 
the anastomosis, during CPB or anastomosis, after CPB or anastomosis, and in ICU). If available, 
we will be collecting the baseline creatinine value. In case of myocardial infarction we will be 
collecting the cardiac biomarker value. Follow-up at 30 days and at one year will focus on the 
adverse cardiac events, hospital readmissions and survival.  
 
Outcomes 
We hypothesize that volatile anesthetics will reduce one-year mortality from any cause in 
participants undergoing CABG surgery.  
Secondary endpoints will include: 30-day all-cause mortality; 30-day non-fatal myocardial 
infarction and 30-day death (composite endpoint); cardiac mortality at 30 days and at one year; 
hospital re-admission during the follow-up period; ICU and hospital stay. We also collect the 
number of adverse events: stroke, delirium, postoperative cognitive impairment, acute renal failure, 
surgical revision for bleeding, high dose inotropic drugs and the use of intra-aortic balloon pump or 
other mechanical circulatory support. Definitions of the outcomes are presented in the 
Supplementary material. To perform 30-days and one-year follow-up telephone contact (patient and 
relatives) will be used. In case loss to follow-up by telephone, the following methods will be used to 
establish vital status at one year: contacting the patient’s general practitioner, contacting the city 
municipality, and sending a letter to the home address of the patient. 
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Statistical analysis and sample size estimates 
An epidemiologist with extensive experience in designing, conducting and analyzing clinical trials, 
not involved in patient management, and blinded to the assigned intervention will be responsible for 
the statistical analysis. 
Data will be stored electronically via a web based CRF and analyzed using STATA (Stata 
Statistical Software: version 14, College Station, TX, USA). We will not apply any imputation for 
missing data. All data will be analyzed according to the intention-to-treat principle, beginning 
immediately after randomization. 
Demographic and baseline disease characteristics will be summarized with the use of descriptive 
statistics. Categorical variables will be reported as absolute numbers and percentages. Unadjusted 
univariate analyses, to compare the two treatment groups, will be based on Chi-square or Fisher’s 
exact test. Relative risks and 95% confidence intervals will be calculated by means of the two-by-
two table method with the use of log-normal approximation. Continuous variables will be reported 
as mean ± standard deviation (SD) or median and interquartile range (IQR). Normality will be 
evaluated using visual histogram evaluation and a Q-Q plot. Between-group differences will be 
evaluated using the T test or Wilcoxon signed rank test, in accordance with normality of the 
distribution. A logistic regression model using a stepwise selection will be used to estimate the 
treatment effect and predictors of mortality. The pre-randomization clinical data and center will be 
entered into the model if their univariate p value is less than 0.1 and there is no correlation between 
them. Collinearity and overfitting will be assessed using a stepwise regression model and Pearson 
correlation test. The treatment group (volatile anaesthetics or TIVA) will be forced into the 
multivariate model. If the outcome event proves to be rare, a Poisson regression model will be used. 
A classic logistic regression will be performed with a consistent number of events and the number 
of covariates in the model will be decided based on the number of outcome events.  
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On the basis of the latest large RCTs comparing CABG versus percutaneous interventions15,16,17,18 
or comparing different CABG techniques,19 we hypothesize a one-year mortality of 3% in the 
control (TIVA) group. Following the results of a recent meta-analysis20 and one large retrospective 
observational study21 demonstrating reduced mortality with the use of volatile anesthetics, we 
hypothesize a reduction in mortality from 3 to 2% in the volatile anesthetic group. Sample-size 
calculation is based on Pearson’s Chi-square test with a two-sided alpha error of 0.05 and 90% 
power. We calculated that we would need a sample size of 5,300 participants per group using the 
continuity correction resulting in the total study population of 10,600 patients. Despite recent 
literature on sample size calculation in multicenter RCTs25, we were unable to use this novel 
method in our competitive-enrolment trial as we did not know a priori the number of participating 
centers and the number of patients per center. We therefore used the conservative approach 
described above, which results in a greater sample size. 
An independent safety committee will perform three interim analyses after recruitment of 25% 
(n=2,650), 50% (n=5,300) and 75% (n=7,950) of patients. Data evaluation at each interim analysis 
will be based on the alpha spending function concept, according to Lan and De Mets’26, and will 
employ O’Brien-Fleming Z-test boundaries27, which are very conservative early in the trial. For the 
first interim analysis the efficacy stopping rule would require an extremely low P value (P< 
0.000015). For the second interim analysis P< 0.003 will be taken as efficacy stopping rule. For the 
third interim analysis P< 0.02 will be taken as efficacy stopping rule. Investigators will be kept 
blind to the interim analysis results. 
The independent safety committee will also perform conditional power analyses in order to evaluate 
potential interruption for futility issues in the trial. Conditional power will be calculated by 
assuming that the proportion of outcomes will follow the observed trend. 
Moreover, if during the first interim analysis the independent safety committee will observe a 
similar direction and magnitude of the study technique effect on 30-day and 1-year mortality, they 
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will be in the position to use 30-day mortality data to suggest study continuation or interruption in 
the following interim analyses. 
All data analyses will be carried out according to a pre-established analysis plan. Because organ 
protection elicited by volatile anesthetics can be modulated by several clinical factors we pre-
specified subgroups analyses that are summarized in Table 2. 
The dosage and mode of anesthetic administration could be confounders in the trial. Therefore, we 
will also separately analyze: centers using volatile agent also during CPB; centers that routinely do 
not use propofol as induction agent in the volatile group; centers with a high overall mortality; 
centers that use volatile anesthetic throughout all the procedure (before CPB, during CPB and after 
CPB); centers using TIVA as main anesthetic technique agent before study initiation; centers using 
volatile agent as main anesthetic technique before study initiation. 
Planned subgroup analyses 
Ejection Fraction <40% 
Patients with diabetes mellitus 
Age <60 years 
Previous: 
- Myocardial infarction 
- Vascular Surgery 
- Stroke or transient ischemic attack 
Chronic kidney disease 
Perioperative beta-blocker use 
On-pump CABG vs Off-pump CABG 
Bypass grafts ≥ 4 
Drug used as volatile agent: 
- Desflurane 
- Isoflurane 
- Sevoflurane 
Drug used as hypnotic agent: 
- Propofol 
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- Midazolam 
Drug used as opioid agent: 
- Remifentanil 
- Fentanyl 
- Sufentanil 
Volatile administration strategy: 
- At least 1 MAC of volatile agent for 30 minutes 
- 15 minutes wash-out period of volatile agent 
- Planned wash-in/wash-out period of the volatile agent 
CABG: Coronary artery bypass graft; MAC: Minimum alveolar concentration. 
Table 2: Planned subgroups analyses. Ejection Fraction will be measured by echocardiography.  
 
Monitoring of the study 
Auditors will verify adherence to required clinical trial procedures and will confirm accurate data 
collection according to the Good Clinical Practice (GCP) guidelines. Study monitoring and follow-
up protocols, from the initial set-up to final reporting, will be fulfilled according to current National 
and International requirements. 
 
Ethical aspects 
This is a randomized trial of different anesthesiological strategies that have been used for decades 
on hundreds of millions of participants. The incidence of adverse events such as malignant 
hyperthermia, allergy and propofol syndrome is negligible, and unavoidable if the patient has to 
undergo general anesthesia. Subjects will not experience any tangible additional risk because of the 
trial. 
Trial data will be stored in an electronic database with no patient identifiers (a numeric code will be 
used). 
 
Study initiation, timing, participating centers and source of funding 
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The study started after Ethical Committee approval from each contributing recruiting center. 
Consecutive participants who sign the written informed consent, aged 18 years or older will be 
enrolled. The study progress will be updated monthly. The first 4500 participants were randomized 
by April 2017 in 32 hospitals and 13 countries. The number of participating centers is continuously 
increasing, as no a priori limit to the number of participating centers has been established. 
The authors are solely responsible for the design and conduct of this study, all study analyses and 
drafting and editing of the paper. 
This trial is funded by the Italian Ministry of Health (RF-2010-2318290). 
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DISCUSSION 
The important innovation in this large multicenter RCT is that it potentially provides 
anesthesiologists with evidence for choosing anesthetics that will lead to the best clinical outcome 
for their patients. To the best of our knowledge this is the largest RCT ever performed on anesthetic 
drugs. 
The inclusion of a volatile anesthetic for CABG is a simple technique that can be applied to all 
patients, as anesthesiologists worldwide are trained in both types of anesthesia delivery, and the 
equipment for both anesthesia techniques are readily available. If the hypothesis is proven correct 
and mortality is reduced, this simple intervention can save over 2,500 lives each year worldwide 
and contribute to reduced health care cost. 
The design of the study is deliberately pragmatic rather than strictly controlled. By allowing a range 
of anesthetic drugs and techniques used by participating institutions, the feasibility and external 
validity is maximized. The inclusion of off-pump CABG is justified by preliminary randomized 
evidence on the efficacy of volatile agents in this group of patients28-31, and differences between 
techniques will be explored in a subgroup analysis.    
The tradeoff for a pragmatic design is to have a conservative estimate of mortality and power the 
study appropriately. Although we are studying an anesthetic intervention, the outcome is highly 
relevant to cardiologists and cardiac surgeons, as survival after coronary intervention is the primary 
reason for performing the operation. 
 
LIMITATIONS 
A possible limitation, that, in our opinion, is also potentially a strength of our study, is that we 
decided not to mandate a strict anesthetic protocol, including different opioids, induction agents, 
cardioplegia fluids, on- or off-pump procedures. This allows all patients to be treated according to 
the best available practice in each center. It also adds external validity to our findings. 
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As the cardioprotective effect of volatile agents may also be diminished by the lack of a strict 
protocol to use volatile agents, we plan to collect data on the dose, length, and timing of 
administration of various volatile agents, in order to better understand how these variables might 
influence the potential benefits of volatile drugs. 
CONCLUSIONS 
The MYRIAD trial will be the first adequately powered RCT comparing the effects of volatile and 
total intravenous anesthetics on survival after CABG. If the predicted effect is proven, 
approximately 2,500 lives could be saved each year worldwide.  
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